Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Payables (2024 - 2025)

Historic Payables for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to $66.8 million.

  • Kura Oncology's Payables rose 8067.41% to $66.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.8 million, marking a year-over-year increase of 8067.41%. This contributed to the annual value of $50.0 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Kura Oncology's Payables stood at $66.8 million, which was up 8067.41% from $52.9 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's Payables peaked at $66.8 million during Q3 2025, and registered a low of $30.9 million during Q1 2024.